The role of GPD2 on ferroptosis in sepsis-induced acute lung injury

分享:

简介:

  • 作者: Ying Han, Chunfang Dai, DanDan Hu, Yu Yao, Wanwan Peng, Yijun Zheng, Qiyi Zeng, Hairui Xie, Jinda Huang
  • 杂志: Biochemical and Biophysical Research Communications
  • Doi: https://www.doi.org/10.1016/j.bbrc.2025.153066
  • 出版日期: 2026/1/1

论文中使用的产品/服务

询价

摘要

Sepsis-induced acute lung injury (ALI) is a serious complication that substantially increases mortality in sepsis. Glycerol-3-phosphate dehydrogenase 2 (GPD2), a mitochondrial enzyme, is involved in oxidative stress, inflammation, and ferroptosis. However, its specific role in sepsis-induced ALI remains unclear. This study explored the role of GPD2 in sepsis-induced ALI. The study employed a cecal ligation and puncture (CLP) mouse model of sepsis, with GPD2 expression knocked down using adeno-associated virus vectors. Selenomethionine (SeMet), a GPX4 activator, was administered 24 h prior to CLP surgery. Increased GPD2 expression was observed in the lungs of septic mice. GPD2 knockdown mice subjected to CLP had a reduced survival rate and exhibited exacerbated lung injury, characterized by increased vascular permeability, neutrophil infiltration, inflammation, and oxidative stress. Moreover, GPD2 knockdown significantly promoted ferroptosis in the lungs of septic mice. Notably, SeMet not only inhibited ferroptosis but also partially reversed the lung injury exacerbated by GPD2 knockdown in septic mice. Our results suggest that GPD2 may protect against pulmonary vascular permeability, neutrophil infiltration, oxidative stress, and inflammatory responses in septic mouse lung tissues by suppressing ferroptosis through the activation of the GPX4 pathway. These findings suggest that GPD2 could be a potential therapeutic target for sepsis-induced ALI.

关于派真

作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IITINDBLA的各个阶段。

 

凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。

下载

用户登录

还没账号? 请注册
手机验证码登录
账号密码登录
手机号码*
验证码*
忘记密码?

首次使用手机号登录将自动为您注册

登录即代表阅读并接受《注册协议》 《用户协议》

新用户注册

已有账号?
手机注册
邮箱注册
手机号码*
验证码*
机构名称*
客户类型*

重置密码

手机找回密码
邮箱找回密码
手机号码*
验证码*
设置新密码*
确认新密码*